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Abstract	  A	   great	   number	   of	   hepatic	   and	   extrahepatic	   immune-­‐system	   disorders	   may	  complicate	  a	  percentage	  of	  patients	  with	  hepatitis	  C	  virus	  (HCV)	  infection	  that	  is	  both	  hepatotropic	   and	   lymphotropic	   agent;	   the	   resulting	   clinical	   phenotypes	   can	   be	  grouped	   into	   the	   so-­‐called	   HCV	   syndrome.	   This	   latter	   includes	   various	   rheumatic	  disorders	   that	   are	   characterized	   by	   frequent	   clinico-­‐serological	   overlap;	   therefore,	  correct	   patients’	   classification	   is	   necessary	   before	   therapeutic	   decisions	   are	   made.	  The	   management	   of	   these	   conditions	   is	   particularly	   difficult	   because	   of	   the	  coexistence	  of	  viral	  infection	  and	  complex	  immunological	  alterations.	  In	  this	  context,	  cryoglobulinemic	   vasculitis	   represents	   the	   prototype	   of	   HCV-­‐related	   rheumatic	  disorders	   that	   can	   be	   treated	   at	   different	   levels	   by	  means	   of	   etiological	   (antivirals)	  and/or	   pathogenetic/symptomatic	   treatments	   (rituximab,	   cyclophosphamide,	  steroids,	  plasmapheresis,	  etc).	  In	  clinical	  practice,	  the	  therapeutic	  strategy	  should	  be	  modulated	  according	  to	  the	  specific	  symptoms	  combination	  and	  the	  severity/activity,	  and	  always	  tailored	  to	  each	  individual	  patient’s	  conditions.	  	  This	   review	   focuses	   on	   the	   clinico-­‐diagnostic	   assessments	   and	   therapeutical	  approaches	  of	  some	  rheumatic	  disorders	  complicating	  HCV	  infection,	  mainly	  arthritis,	  sicca	   syndrome,	   and	   osteosclerosis;	   while,	   cryoglobulinemic	   vasculitis	   is	  comprehensively	  examined	  in	  another	  article	  of	  the	  present	  issue.	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Introduction	  Hepatitis	  C	  virus	  (HCV)	  is	  a	  member	  of	  the	  Flaviviridae	  family,	  	  splitted	  into	  7	  major	  genotypes,	   globally	   distributed,	   even	   though	   with	   wide	   geographic	   variations.	  Discovered	   in	   the	   early	   1990s,	   it	  was	   recognized	   as	   the	   cause	   of	   the	   former	   non-­‐A/non-­‐B	   chronic	   hepatitis	   (1);	   moreover,	   several	   epidemiological,	   clinico-­‐pathological,	  and	  laboratory	  studies	  definitely	  ascertained	  the	  etiologic	  role	  of	   this	  virus	   in	   mixed	   cryoglobulinemia	   syndrome	   (MCs)	   or	   cryoglobulinemic	   vasculitis	  (CV)	  (2,	  3);	  these	  synonyms	  are	  referred	  to	  systemic	  autoimmune	  disease,	  typically	  featured	  by	   serum	  mixed	   cryoglobulins,	   orthostatic	  purpura,	   and	  variable	   visceral	  organ	   involvement	   (4-­‐7).	   	   In	  particular,	   the	  demonstration	  of	  HCV	   lymphotropism	  represented	  a	   crucial	  point	   in	   the	  knowledge	  of	   the	  pathogenesis	  of	  CV	  and	  other	  autoimmune	   disorders	   potentially	   associated	   to	   HCV	   (8,	   9).	   The	   majority	   of	  individuals	  with	  HCV	  infection	  are	  asymptomatic,	  often	  for	   long-­‐time	  period	  or	  for	  their	   entire	   life,	   and	   only	   a	   limited	   but	   relevant	   number	   of	   subjects	  may	   develop	  hepatic	   as	   well	   as	   extrahepatic	   diseases;	   these	   latter	   frequently	   represent	   a	   late	  complication	  of	  long-­‐lasting	  viral	  infection	  (4,	  10).	  	  We	  previously	  proposed	  the	  term	  'HCV	  syndrome'	  referring	  to	  the	  constellation	  of	  virus-­‐driven	  clinical	  conditions	  (11),	  including	  both	  hepatic,	  organ-­‐specific,	  systemic	  autoimmune	  disorders,	  and	  also	  malignancies	  (4,	  6,	  7,	  10,	  11).	  The	  different	  clinical	  phenotypes	   of	   HCV-­‐syndrome	   can	   be	   the	   results	   of	   genetic/environmental	   co-­‐factors	  as	   suggested	  by	   the	  heterogeneous	  geographical	  prevalence	  of	   single	  HCV-­‐associated	   manifestations,	   and	   it	   is	   now	   clear	   that	   some	   genetic	   variants	   in	   HCV	  infected	  people	  can	  predispose	  to	  the	  development	  of	  CV,	  in	  particular	  with	  regard	  to	  the	  MHC	  class	  II	  and	  NOTCH4	  genes	  (4,	  6,	  7,	  10-­‐15).	  	  A	  number	  of	   rheumatic	  disorders	   can	  be	   correlated	   to	  HCV	   infection,	   even	   if	  with	  largely	   variable	   frequency.	   The	   prototype	   of	   such	   etiopathogenetic	   linking	   is	   the	  HCV-­‐related	  MCs,	  while	  for	  some	  other	  conditions	  the	  association	  is	  just	  anecdotally	  observed	   (4,	   10,	   11,	   16-­‐20;	   Fig.	   1).	   It	   is	   relatively	   frequent	   to	   observe	   a	   clinical	  overlap	   between	   CV	   and	   other	   rheumatological	   disorders,	   mainly	   Sjögren’s	  syndrome	  (SS)	  or	  rheumatoid	  arthritis	  (RA)	  (4,	  10,11,	  16,	  17,	  11-­‐23;	  Fig.	  2).	  	  In	  other	  cases,	  the	  latter	  rheumatic	  diseases	  are	  independently	  associated	  to	  the	  chronic	  HCV	  infection.	  	  	  
Therapeutic	  strategies	  of	  HCV-­related	  rheumatic	  diseases.	  Therapeutic	   approach	   to	   different	   HCV-­‐related	   disorders,	   including	   rheumatic	  diseases,	  should	  be	  chosen	  on	  the	  basis	  of	  the	  etiopathogenetic	  cascade	  responsible	  for	   HCV	   syndrome	   (Fig.	   3,	   left).	   This	   is	   a	   multifactorial	   and	   multistep	   process	  possibly	   promoted	   by	   different	   co-­‐factors;	   namely,	   	   HCV	   infection,	   predisposing	  genetic	  factors	  and,	  possibly,	  unknown	  environmental/toxic	  triggers	  (6,	  8,	  24).	  The	  HCV	   lymphotropism	   may	   trigger	   complex	   immune-­‐system	   alterations	   with	  prominent	   ‘benign’	   lymphoproliferation,	   from	   one	   side,	   as	   well	   as	   important	  oncogenetic	   abnormalities,	   from	   another	   side.	   These	   pathological	   chances	  may	   be	  the	   result	   of	   different	   pathogenetic	   mechanisms	   not	   mutually	   exclusive:	   viral	  antigens	  (core,	  envelope	  E2,	  NS3,	  NS4,	  NS5A	  proteins)	  may	  exert	  a	  chronic	  stimulus	  on	   the	   host	   immune	   system,	   the	   high-­‐affinity	   binding	   between	  HCV-­‐E2	   and	   CD81	  and	   consequent	   t(14;18)	   translocation	   with	   bcl-­‐2	   proto-­‐oncogene	   activation,	   a	  cross-­‐reaction	   between	   particular	   HCV	   antigens	   and	   host	   autoantigens,	   i.e.	   a	  molecular	   mimicry	   mechanism,	   and	   a	   direct	   infection	   of	   B-­‐lymphocytes	   by	   HCV	  directly	   responsible	   for	   neoplastic	   cell	   transformation	   (25-­‐27).	   Predisposing	   host	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factors	   may	   include	   particular	   HLA	   alleles,	   and	   both	   metabolic	   and	   hormonal	  conditions	   (28-­‐37).	   The	   main	   consequence	   is	   a	   ‘benign’	   B-­‐cell	   proliferation	   with	  production	   of	   various	   autoantibodies,	   among	   which	   rheumatoid	   factor	   (RF)	   and	  cryo-­‐	   and	   non-­‐cryoprecipitable	   immune	   complexes	   (IC).	   These	   serological	  alterations	   may	   be	   correlated	   with	   different	   organ-­‐	   and	   non-­‐organ-­‐specific	  autoimmune	  disorders,	   including	  the	  systemic	  manifestations	  of	  CV.	  Moreover,	   the	  activation	  of	  Bcl2	  proto-­‐oncogene,	  responsible	  for	  prolonged	  B	  cell	  survival,	  and	  the	  miR-­‐26b	   downregulation	   may	   be	   predisposing	   conditions	   to	   a	   frank	   B-­‐cell	   non-­‐Hodgkin’s	   lymphomas	   (B-­‐NHL)	   and	   other	   malignancies,	   mainly	   hepatocellular	  carcinoma	   (HCC)	   and	   papillary	   thyroid	   cancer	   (4,	   6,	   8,	   9,	   11,	   29,	   38-­‐50).	   The	  appearance	  of	  malignant	  neoplasias	  can	  be	  seen	  in	  a	  small	  but	  significant	  percentage	  of	   patients,	   usually	   as	   a	   late	   complication	   (45-­‐47).	   Both	   immunological	   and	  neoplastic	   disorders	   show	   a	   clinico-­‐serological	   and	   pathological	   overlap.	   Often,	  autoimmune	  organ-­‐specific	  manifestations	  may	  evolve	  to	  systemic	  conditions,	  such	  as	   CV,	   and	   less	   frequently	   to	   overt	  malignancies.	   Conversely,	   it	   is	   not	   uncommon	  that	  patients	  with	  malignancies	  develop	  one	  or	  more	  autoimmune	  manifestations.	  In	  this	   scenario,	   CV	   is	   at	   the	   crossing	   road	   between	   autoimmune	   and	   neoplastic	  disorders	  (4,	  6,	  11,	  24,	  51).	  	  There are not comprehensive therapeutical guidelines for the HCV syndrome because of 
the complexity of its pathogenetic and clinico-prognostic characteristics; we can adopt in 
part the therapeutical strategy used for MCs, which often encompasses the different 
clinical variants of HCV syndrome. This therapeutical approach is essentially based on 
three main levels of intervention: 1. the etiological treatment, by means of antiviral drugs 
directed at HCV eradication; 2. the pathogenetic therapies, with immunomodulating 
and/or antineoplastic drugs; 3. the pathogenetic/symptomatic therapies, such as 
corticosteroids and plasma exchange (4, 12, 52; Fig. 3, right).	  The	  following	  paragraphs	  focus	  on	  some	  rheumatic	  diseases	  potentially	  correlated	  to	   HCV	   infection,	   namely	   arthritis,	   sicca	   syndrome,	   and	   ostheosclerosis,	  while	   the	  treatment	   of	   classical	   CV	   is	   considered	   in	   detail	   in	   another	   article	   of	   the	   present	  issue.	  	  
Arthritis	  The	  presence	  of	  arthritis	  has	  been	  described	  in	  about	  2-­‐3	  percent	  of	  individuals	  with	  chronic	   HCV	   infection;	   in	   fact,	   while	   arthralgias	   can	   be	   included	   among	   the	   most	  frequent	  symptoms	  (60-­‐70%)	  of	  HCV-­‐positive	  patients,	  clear	  signs	  of	  sinovitis	  are	  less	  commonly	  observed	  (4,	  10,	  16,	  22).	  Furthermore,	   a	   few	   cohort	   studies	   have	   suggested	   an	   etiologic	   role	   of	   HCV	   in	   RA	  patients;	   however,	   to	  date,	   clear	   evidence	  of	   a	  pathogenetic	   role	  of	  HCV	   in	  patients	  with	  classical	  RA	  is	  leaking	  (41-­‐47,	  51-­‐57).	  Furthermore,	  a	  specific	  entity	  called	  HCV-­‐related	  arthritis	  has	  been	  hypothesized;	  it	  is	   classified	   as	   a	   ‘reactive’	   arthritis,	   even	   though	   in	   some	   individuals	   HCV-­‐related	  chronic	  polyarthritis	  may	  mimic	  classical	  RA.	  In	  these	  instances,	  a	  clear	  distinction	  of	  this	   clinical	   variant	   from	   classical	   RA	   is	   often	   difficult	   (Fig.	   2).	  Moreover,	   arthritis	  due	   to	  HCV	   is	   frequently	  described	   as	   "rheumatoid-­‐like",	  mainly	   in	   the	  presence	  of	  chronic	  symmetrical	  polyarthritis;	  more	   than	  50%	  of	   these	  patients	  may	  satisfy	   the	  criteria	  for	  RA	  classification;	  namely,	  arthritis	  of	  three	  or	  more	  joint	  areas,	  arthritis	  of	  hand	   joints,	   symmetric	   arthritis,	   alteration	   of	   acute-­‐phase	   reactants,	   and	   RF	  seropositivity	  (58).	  Usually,	  HCV-­‐related	  polyarthritis	  shows	  a	  benign,	  often	  fluctuating	  clinical	  course	  (4,	  10,	   11,	   52).	   The	  majority	   of	   patients	   develop	   polyarticular	   disease,	   being	   the	   small	  joints	  (metacarpophalangeal,	  proximal	   interphalangeal,	  wrists	  and	  ankles)	  primarily	  involved;	   in	   some	  patients	   synovitis	  may	  also	  affect	   shoulders	  and	  knees,	   and	   large	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joint	  effusions	  have	  been	  described	  in	  10-­‐30%	  of	  cases	  as	  mono-­‐/oligoarthritis	  (4,	  10,	  16,	  22,	  57).	  The	  presence	  of	  serum	  rheumatoid	  factor	  is	  quite	  common,	  in	  the	  absence	  of	   rheumatoid	   nodules,	   periarticular	   osteopenia	   or	   articular	   destruction,	   even	   if	  erosive	  findings	  can	  be	  observed	  in	  1/3	  of	  cases	  (4,	  10,	  16,	  22,	  57).	  The	  erythrocyte	  sedimentation	  rate	  is	  within	  normal	  limits	  in	  about	  half	  patients;	  more	  interestingly,	  serum	  anti-­‐cyclic	  citrullinated	  peptide	  (anti-­‐CCP)	  antibodies	  are	  invariably	  absent	  in	  HCV-­‐related	  oligo-­‐/polyarthritis	  with/without	  cryoglobulinemia	  (4,	  10,	  16,	  22;	  Fig.	  4).	  A	   peculiar	   subset	   of	   HCV	   patients	   with	   arthritis	   is	   represented	   by	   CV-­‐associated	  arthritis.	  The	   latter	  usually	   is	  oligo-­‐monoarticular,	  affecting	  the	   large	   joints	  of	   lower	  limbs,	   where	   the	   purpuric	   lesions	   are	   particularly	   frequent;	   furthermore,	   it	   is	  generally	   asymmetrical,	   intermittent,	   non-­‐erosive,	   and	   characterized	   by	   better	  prognosis	  (4,	  10,	  16,	  22,	  57).	  Finally,	   given	   the	   relatively	   high	   prevalence	   of	   both	   HCV	   infection	   and	   RA	   in	   the	  general	   population	   it	   is	   not	   rare	   to	   observe	   a	  mere	   association	  between	   the	   virus	  and	  RA.	  Therefore,	   a	  virological	  and	  clinico-­‐serological	  evaluation	   is	  mandatory	   in	  all	   cases	   of	   patients	   referred	   for	   arthritis	   in	   order	   to	   detect	   the	   presence	   of	   HCV	  infection;	   in	   this	   instance,	   the	   differential	   diagnosis	   between	   the	   simple	  comorbidity,	   i.e.	   classical	   RA	   plus	   HCV	   infection,	   and	   HCV-­‐related	   arthritis	   is	  necessary	  (59-­‐63;	  Fig.	  4).	  In	   patients	   with	   concomitant	   HCV	   infection	   and	   arthritis	   (Fig.	   3-­‐4)	   the	   treatment	  may	   include	   both	   antivirals	   (12,	   49,	   50,	   52,	   60,	   61)	   and	   immune-­‐modulating	  treatments,	   i.e.	   steroids,	   hydroxychloroquine,	   other	   disease-­‐modifying	   anti-­‐rheumatic	  drugs	  (DMARDs);	  when	  necessary,	  the	  use	  of	  biological	  DMARDs	  such	  as	  tumour-­‐necrosis-­‐factor-­‐alpha-­‐blocking	   agents	   (anti-­‐TNF-­‐alpha)	   or	   rituximab,	   seem	  to	  be	  useful	  and	  safe	  (16,	  53,	  55,	  65-­‐67).	  	  On	   the	   contrary,	   the	   gold	   standard	   treatment	   of	  HCV-­‐related	   arthritis	   has	   not	   yet	  been	  established	  and	  can	  be	  particularly	  difficult	  in	  the	  majority	  of	  treated	  patients.	  Generally,	   treatment	  with	  hydroxychloroquine	   (HCQ)	   and	   low	  doses	   of	   steroids	   is	  safe	   and	   effective	   in	   controlling	   arthritic	   manifestations,	   even	   in	   association	   to	  antiviral	   treatment.	   However,	   careful	   monitoring	   of	   interferon-­‐alpha	   (IFNα)	   and	  ribavirin	  treatment	  is	  mandatory,	  owing	  to	  the	  potential	  ‘arthritogenic’	  effect	  due	  to	  the	  immunoregulatory	  properties	  of	  IFNα;	  indeed	  the	  use	  of	  IFNα	  may	  be	  associated	  with	  adverse	  effects,	  including	  the	  worsening	  of	  arthropathy,	  despite	  its	  usefulness	  in	  the	  treatment	  of	  type	  C	  hepatitis	  (2,	  16,	  52-­‐54,	  67-­‐74).	  The	   recent	   introduction	   of	   interferon-­‐free	   anti-­‐HCV	   therapies	   seems	   to	   be	   very	  promising;	  it	  may	  lead	  to	  viral	  eradication	  without	  the	  above-­‐mentioned	  side-­‐effects	  (75-­‐77,	  Zignego	  et	  al.	  in	  this	  issue).	  In	  summary,	  we	  can	  classify	  patients	  with	  HCV	   infection	  and	  arthritis	  as	  a)	  simple	  comorbidity	   -­‐HCV	   infection	   and	   definite	   RA-­‐	   and	   b)	   HCV-­‐related	   arthritis	   in	   the	  setting	   of	   apparently	   isolated	   HCV	   infection	   with	   more	   or	   less	   recognizable	   liver	  involvement	  or	  in	  the	  context	  of	  MCs	  (53;	  Fig.	  4).	  The	  first	  condition	  may	  be	  treated	  with	  the	  strategies	  commonly	  used	  for	  RA	  with	  some	  precautions	  in	  consideration	  of	  the	  concomitant	  viral	   infection	  and	  possible	   liver	   involvement.	  Besides	  HCQ,	  other	  traditional	   DMARDs,	   i.e.	   methotrexate	   or	   leflunomide,	   may	   be	   used	   after	   careful	  liver	  involvement	  evaluation;	  while	  biologics	  such	  as	  anti-­‐TNF-­‐alpha	  and	  rituximab	  can	   be	   usefully	   employed	   without	   significant	   side-­‐effects	   in	   HCV-­‐positive	   RA	  patients	   (16,	   53,	   55,	   63,	   65-­‐67).	   Indeed,	   careful	   hepatologic	   evaluation	   of	   these	  patients	   is	   always	   mandatory,	   taking	   into	   account	   the	   opportunity	   of	   antiviral	  treatments	  (52,	  64,	  67,	  70,	  71).	  On	  the	  whole,	  patients	  with	  concomitant	  RA	  and	  HCV	  infection	   deserve	   the	   same	   clinical	   assessment	   and	   monitoring	   of	   HCV-­‐related	  arthritis	  with/without	  CV;	  yet,	  they	  may	  present	  an	  increased	  risk	  to	  develop	  some	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HCV-­‐associated	   complications	   including	   B-­‐cell	   NHL,	   even	   as	   consequence	   of	  immunomodulating	  therapies	  (16,	  52,	  53,	  55,	  63,	  65-­‐67).	  	  	  	  
Sicca	  syndrome	  	  While	   the	  possible	   involvement	  of	  HCV	   in	   the	  pathogenesis	  of	  Sjögren’s	   syndrome	  (SS)	   is	   still	  a	   controversial	   topic	   (17,	  78-­‐80;	  Fig.	  2),	  differential	  diagnosis	  between	  CV	  and	  primary	  SS	  may	  be	  very	  difficult	   in	   individual	   cases,	   such	  as	  patients	  with	  sicca	   syndrome,	   serum	  mixed	  cryoglobulins,	  HCV	   infection,	   and	  anti-­‐RoSSA/LaSSB	  antibodies;	   these	   latter	   generally	   at	   low	   serum	   concentration	   (17,	   78-­‐80).	   This	  peculiar	   symptom	   complex	   that	  may	   satisfy	   classification	   criteria	   of	   both	   CV	   and	  primary	  SS	  seems	  to	  identify	  a	  worse	  clinical	  variant,	  more	  frequently	  complicated	  by	  malignant	   lymphoma	  (17,	  78-­‐80).	   It	   is	  preferable	  to	  consider	  patients	  with	  this	  peculiar	   condition	   as	   having	   overlapping	   SS/CV	   syndrome	   that	   should	   be	   treated	  according	  to	  individual,	  prominent	  clinical	  manifestations	  (17,	  53,	  78-­‐80).	  	  The	  presence	   in	  the	  clinical	  practice	  of	  overlapping	  SS/CV	  syndrome	  suggests	   that	  HCV	  may	  trigger	  complex	  immunological	  alterations	  that,	  in	  genetically	  predisposed	  subjects,	  may	  cause	  various	  clinical	  phenotypes	  mimicking	  distinct	  or	  a	  combination	  of	  well-­‐known	  disorders,	  such	  as	  RA,	  SS,	  dermato-­‐polymyositis,	  etc.	  (16,	  17,	  53)	  (Fig.	  3).	  Antiviral	  treatment	  with	  IFNα	  and	  ribavirin	  seems	  to	  improve	  the	  sicca	  syndrome	  in	  HCV-­‐positive	  patients,	  even	  if	  serious	   immune-­‐mediated	  adverse	  events	  have	  been	  observed	   (16,	   52-­‐54,	   67-­‐74).	   Besides	   topical	   treatments	   and	   hygienic	   precautions	  that	  may	  partially	  improve	  the	  patient’s	  quality	  of	  life,	  there	  is	  not	  specific	  systemic	  treatment	  of	  HCV-­‐infected	  patients	  with	  apparently	  isolated	  sicca	  syndrome.	  It	  can	  be	  managed	   in	   the	   context	   of	   underlying	   disorder,	   from	   type	   C	   hepatitis	   to	   overt	  MCs.	  As	  for	  CV	  or	  SS,	  the	  possible	  complication	  with	  malignant	  lymphomas	  must	  be	  taken	  into	  account	  also	  in	  these	  patients	  (17,	  80).	  	  	  
Osteosclerosis	  	  Osteosclerosis	  is	  a	  very	  uncommon	  condition	  described	  in	  adults	  infected	  with	  HCV	  (16,	  53,	  81-­‐85);	  since	  1992,	  about	  20	  cases	  of	  HCAO	  have	  been	  reported	  in	  patients	  who	   	  acquired	  hepatitis	  C	   from	  blood	  transfusions	  and	  even	  possibly	  acupuncture,	  rather	   than	   intravenous	   drug	   abusers;	   it	   can	   be	   defined	   as	   an	   acquired,	   painful	  skeletal	  disorder	  characterized	  by	  a	  marked	  increase	  of	  bone	  mass	  (16,	  53,	  81-­‐87).	  Clinically,	  osteosclerosis	  is	  characterized	  by	  nonspecific,	  often	  diffuse	  bony	  pain	  and	  tenderness	  over	  involved	  bones	  due	  to	  periosteal	  stretching,	  in	  the	  absence	  of	  joint	  swelling	   or	   motion	   limitation.	   Radiograph	   examination	   shows	   bony	   sclerosis	   and	  thickening	   of	   the	   long-­‐bone	   cortices,	   mainly	   diaphyseal	   cortices.	   Laboratory	  investigations	   frequently	   reveal	   abnormally	   increased	  markers	   of	   bone	   formation	  (alkalinephosphatase	   (ALP)	   and	   bone-­‐specific	   ALP,	   osteocalcin);	   these	   serological	  alterations	   were	   mirrored	   by	   the	   marked	   increase	   of	   bone	   mass	   (BMD)	   and	  enhanced	   radionuclide	   uptake	   at	   scintigraphy	   (99mTc-­‐MDP).	   Bone	   biopsy	   shows	  increased	   number	   and	   thickness	   of	   trabeculae	   with	   parallel	   reduction	   of	   bone	  marrow	   (16,	   81-­‐87).	   Compared	   to	   the	   large	   diffusion	   of	   HCV,	   only	   a	   very	   small	  percentage	  of	  infected	  patients	  may	  develop	  osteosclerosis.	  The	  pathogenesis	  of	  this	  rare	   syndrome	   is	   still	   unknown.	   It	   has	   been	   suggested	   that	   HCV	   alone	   or	   in	  combination	   of	   other	   unknown	   agent(s)	   may	   infect	   and	   alter	   bone	   cells	   or	   their	  precursors	  in	  predisposed	  subjects.	  These	  specific	  alterations	  might	  be	  mediated	  by	  the	   production	   of	   bone	   growth	   factors,	   such	   as	   insulin-­‐like	   growth	   factors	   or	  osteoprotegerin	   (81-­‐86).	   The	   pathogenetic	   role	   of	   this	   latter	   factor	   seems	   to	   be	  relevant;	   an	   imbalance	   in	   the	   osteoprotegerin/RANKL	   system	   leading	   to	   a	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predominance	  of	  osteoprotegerin	  has	  been	  documented	  (81-­‐87).	  Less	  than	  20	  cases	  of	  HCV-­‐associated	  osteosclerosis	  were	  described	  to	  date	  (16,	  53,	  83-­‐87);	  besides	  the	  possible	   relevance	   in	   the	  clinical	  practice,	   this	  disorder	  presents	   some	  stimulating	  suggestions	  as	  regards	  virus-­‐driven	  autoimmunity	  and	  bone	  tissue	  alterations.	  The	  treatment	  with	  anti-­‐resorptive	  agents	  in	  at	  least	  seven	  patients	  was	  ineffective	  (16,	  53,	  81-­‐87);	  while	   symptomatic	   treatments	  may	  provide	   some	  benefit	   (16,	  53,	  81-­‐87).	   In	   individual	   cases	   a	   partial	   or	   complete	   spontaneous	   remission	   of	  symptoms	  and/or	  bone	  sclerosis	  was	  observed	  during	  the	  follow-­‐up	  (53,	  81-­‐87).	  	  Of	  interest,	  in	  a	  recently	  published	  case	  report	  (83)	  the	  antiviral	  therapy	  was	  followed	  by	   a	   recovery	   of	   skeletal	   sclerosis.	   The	   beneficial	   role	   of	   HCV	   eradication	   is	  particularly	  intriguing	  and	  should	  be	  confirmed	  in	  larger	  number	  of	  patients.	  	  	  
Miscellanea	  	  The	  number	  of	  HCV-­‐associated	  rheumatic	  diseases,	  as	  well	  as	  of	  other	  extrahepatic	  disorders,	  has	  progressively	  grown	  during	  the	  last	  two	  decades.	  Besides	  CV	  and	  the	  pathologic	   conditions	   described	   above,	   other	   rheumatic	   diseases	   have	   been	  associated	  to	  HCV	  infection;	  namely,	  myalgias,	  fibromyalgia,	  poly/dermatomyositis,	  polyarteritis	   nodosa,	   Behçet's	   syndrome,	   systemic	   lupus	   erythematosus,	   and	   anti-­‐phospholipid	  syndrome	  (4,	  16,	  21,	  88;	  Fig.	  1).	  The	   appearance	   of	   these	   disorders	   may	   be	   mainly	   correlated	   to	   specific	   host	  susceptibility	  to	  autoimmune	  disorders,	  as	  well	  as	  to	  viral	  factors	  such	  as	  different	  HCV	  genotypes,	  and/or	  variable	  contribution	  of	  unknown	  environmental	  co-­‐factors	  (4,	  6,	  7,	  10,	  11,	  16,	  21,	  88).	  Myalgia	  has	  been	   referred	  by	  a	   significant	  number	  of	  patients	   (15%)	   from	  a	   large	  series	   of	  HCV-­‐infected	   individuals	   (16,	   21,	   88).	   The	  pathogenesis	   of	   this	   symptom	  remains	  difficult	  to	  explain;	  the	  detection	  of	  viral	  genomic	  sequences	  within	  muscle	  fibers	  suggested	  a	  direct	  involvement	  of	  HCV	  in	  the	  pathogenesis	  of	  diffuse	  muscle	  pain	   (89).	   Fibromyalgia	   have	   also	   reported	   by	   some	   Authors	   in	   a	   significant	  percentage	  of	  patients	  with	  chronic	  HCV	  infection	  (90);	  but	  other	  studies	  carried	  out	  in	   patients	   with	   typical	   clinical	   manifestations	   of	   fibromyalgia	   did	   not	   confirm	   a	  significant	   association	   (91).	  On	   the	   other	   hand,	   the	   differential	   diagnosis	   between	  fibromyalgia	   and	  muscle	   pain,	   frequently	   associated	   to	  weakness	   and	   arthralgias,	  may	   be	   very	   difficult	   in	   the	   setting	   of	  HCV-­‐positive	   patients,	  mainly	   in	   those	  with	  overt	  MCs	  (16,	  21,	  88).	  As	  for	  sicca	  syndrome	  and	  primary	  SS,	  some	  Authors	  suggest	  to	   consider	   the	  HCV-­‐associated	  myalgias	   and	   the	   classical	   fibromyalgia	   as	   distinct	  entities	  (90).	  Several	  case	  reports	  are	  present	  in	  the	  literature	  regarding	  the	  association	  of	  poly-­‐dermatomyositis	  with	  HCV	  infection	  (21,	  88,	  92).	  Generally,	  these	  disorders	  appear	  in	  patients	  with	  long-­‐lasting	  viral	  infection	  or	  may	  complicate	  IFN	  treatment	  (16,	  21,	  88).	   Similarly,	   cases	   of	   vasculitis	   involving	   medium-­‐sized	   arteries	   suggesting	   the	  diagnosis	   of	   polyarteritis	   nodosa	   have	   been	   associated	   to	   HCV	   infection	   (93);	   in	  addition,	   HCV	   seropositivity	   has	   been	   reported	   in	   a	   significant	   percentage	   of	  patients	  with	  polyarteritis	  nodosa	  (94).	  This	  possible	  association	  is	  not	  surprising	  in	  consideration	   of	   the	   well-­‐known	   relationship	   between	   polyarteritis	   nodosa	   and	  another	  hepatotropic	  virus,	  the	  HBV,	  responsible	  for	  a	  relevant	  number	  of	  patients	  with	   this	   vasculitis	   (95).	   Polyarteritis	   nodosa	   may	   share	   numerous	   clinical	  symptoms	   with	   CV;	   thus,	   patients	   with	   suspected	   HCV-­‐associated	   polyarteritis	  nodosa	   should	   be	   correctly	   classified	   by	   means	   of	   wide	   clinico-­‐serological	   and	  pathological	  work-­‐up.	  As	  regards	  other	  possible	  HCV-­‐associated	  disorders,	  namely	  Behçet's	   syndrome,	   systemic	   lupus	   erythematosus,	   and	   anti-­‐phospholipid	  syndrome,	  data	  reported	  in	  the	  literature	  are	  generally	  anecdotal	  (16,	  21,	  88).	  Even	  if	  a	  possible	  causative	  role	  of	  HCV	   in	   these	  autoimmune	  diseases	  cannot	  be	  totally	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excluded,	   these	  patients	  might	  be	  better	  classified	  as	  having	  a	  simple	  comorbidity.	  However,	   they	   invariably	   represent	   a	   troublesome	   clinical	   condition	   mainly	   with	  regards	  the	  therapeutical	  approach.	  	  
 	  
Conclusions	  Considering	   the	   complexity	   of	   HCV	   syndrome,	   due	   to	   its	   variable	   composition	   of	  clinical	   symptoms	   with	   specific	   pathogenetic,	   clinical,	   and	   prognostic	  characteristics,	  it	  is	  impossible	  to	  draw	  comprehensive	  therapeutical	  guidelines.	  	  In	  clinical	  practice,	  it	  can	  be	  useful	  to	  look	  at	  the	  therapeutical	  strategy	  developed	  for	  patients	  with	  MCs,	  which	  encompasses	  the	  clinical	  variants	  of	  HCV	  syndrome,	  from	  organ-­‐specific	  disorders	   to	  systemic	  autoimmune/neoplastic	  complications	  (Fig.	  3;	  4,	  10-­‐12,	  17,	  20,	  83,	  92-­‐97).	  This	  therapeutic	  strategy	  is	  essentially	  based	  on	  three	  main	   levels	   of	   intervention	   (Fig.	   3):	   etiological,	   pathogenetic,	   and/or	   symptomatic	  therapies;	  these	  three	  different	  therapeutic	   lines	  are	  not	  mutually	  exclusive	  (4,	  12,	  46).	  The	  preemptive	  use	  of	  the	  novel	  interferon-­‐free	  antiviral	  drugs	  in	  HCV-­‐infected	  individuals	  even	  in	  the	  absence	  of	  relevant	  clinical	  manifestations	  is	  a	  very	  critical	  issue,	  considering	  the	  necessary	  cost-­‐benefit	  analysis	  (45,	  46,	  60,	  73,	  Zignego	  et	  al.	  in	  this	  issue).	  	  On	  the	  other	  hand,	  clinico-­‐biological	  parameters	  predictive	  of	  possible	  recovery	  of	  immune-­‐system	   alterations	   after	   HCV	   eradication	   are	   still	   lacking.	   Combined	  pathogenetic	   and	   symptomatic	   therapies	  may	   be	   able	   to	   improve	   the	   presence	   of	  one	  or	  more	  severe/active	  clinical	  symptoms	  of	  HCV	  syndrome,	  including	  rheumatic	  manifestations;	  the	  clinical	  usefulness	  of	  these	  treatments	  has	  been	  largely	  reported	  in	   cryoglobulinemic	   patients,	   particularly	   for	   patients	   treated	   with	   anti-­‐CD20	  monoclonal	  antibody	  therapy	  (45,	  46,	  60-­‐63;	  see	  Giuggioli	  et	  al.	  in	  this	  issue).	  	  The	   etiological,	   pathogenetic,	   and	   symptomatic	   treatments,	   in	   sequence	   or	   in	  combination,	   should	   be	   tailored	   on	   the	   single	   patient	   after	   a	   careful	   clinical	  evaluation	  (4,	  12,	  45,	  46,	  60-­‐63).	  Given	   the	  possible	  complication	  of	  HCV	   infection	  with	  severe,	  life-­‐threatening	  manifestation;	  a	  long-­‐term	  clinical	  monitoring	  of	  HCV-­‐infected	   patients,	   including	   those	   with	   mild	   or	   asymptomatic	   clinical	   variants,	   is	  mandatory.	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  Legend	  to	  Figures	  
Figure	  1.	  Schematic	  representation	  of	  the	  constellation	  of	  HCV-­‐associated	  disorders.	  The	  strength	  of	   this	   association,	   based	   on	   literature	   data,	   is	   represented	   as	   the	   distance	   from	   the	  centre	  of	  the	  figure.	  	  
	  
	  
Figure	  2. Differential	  diagnosis	  of	  HCV-­‐related	  rheumatic	  diseases. 
HCV: hepatitis C virus; SS: Sjögren’s syndrome; RF: rheumatoid factor; Cryo: 
cryoglobulins; anti-CCP: anti-cyclic citrullinated peptides antibodies; NHL: non-Hodgkin 
lymphoma. 




Left:	   the	   etiopathogenetic	   cascade	  of	  HCV	   syndrome	   is	   a	  multifactorial	   and	  multistep	  process,	  which	  leads	  to	  different	  organ-­‐	  and	  non-­‐organ-­‐specific	  autoimmune	  disorders,	  including	  cryoglobulinaemic	  vasculitis	  and	  B	  cell	  lymphomas	  (B-­‐NHL).	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Right:	   therapeutical	   guidelines	   for	   the	   HCV	   syndrome;	   we	   can	   adopt	   in	   part	   the	  therapeutical	   strategy	   used	   for	   MCs,	   which	   often	   encompasses	   the	   different	   clinical	  variants	   of	   HCV	   syndrome.	   This	   therapeutical	   approach	   is	   essentially	   based	   on	   three	  main	   levels	   of	   intervention:	   the	   etiological	   treatment	   by	   means	   of	   antiviral	   drugs	  directed	   at	   HCV	   eradication,	   the	   pathogenetic	   therapies	   with	  immunomodulating/antineoplastic	   drugs,	   and	   the	   pathogenetic/symptomatic	  therapies.	  HCV:	   hepatitis	   C	   virus;	   IC,	   immune	   complexes;	   SS:	   sicca	   syndrome;	   PCT:	   porphyria	  cutanea	  tarda;	  LAC-­‐diet:	  low-­‐antigen-­‐content	  diet;	  CPX:	  cyclophosphamide.	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Figure	  4.	  Clinical	  assessment	  and	  therapeutic	  strategies	  of	  HCV-­‐related	  arthritis.	  
HCV: hepatitis C virus; RA: rheumatoid arthritis; RF: rheumatoid factor; Cryo: 
cryoglobulins; MC: mixed cryoglobulinemia; anti-CCP: anti-cyclic citrullinated peptides 
antibodies;  HCQ: hydroxychloroquine; DMARDs: disease modifying anti-rheumatic drugs.	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